stage 4 Uterine clear-cell carcinoma alternatives

Treatment options and management alternatives for stage 4 uterine clear-cell carcinoma (UCCC), a high-risk subtype of endometrial cancer, integrate surgical, systemic, radiation, and emerging targeted therapies tailored by molecular classification.

In advanced stage IV disease, including stage 4 UCCC, primary surgery's role is controversial but may be considered when complete macroscopic resection is achievable with acceptable morbidity, as cytoreductive surgery has been associated with improved survival outcomes in advanced endometrial cancer (EC) Cassaniti et al. 2026 Cassaniti et al. 2026. When upfront surgery is not feasible due to unresectable disease extent, neoadjuvant chemotherapy followed by interval debulking surgery is a reasonable alternative Cassaniti et al. 2026 Cassaniti et al. 2026.

The systemic treatment backbone for advanced UCCC typically consists of platinum-based chemotherapy, such as carboplatin plus paclitaxel, based on evidence extrapolated from high-grade EC management Cassaniti et al. 2026 Cassaniti et al. 2026. Recent advances have introduced the addition of immune checkpoint inhibitors (ICIs), particularly for patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) tumors; these combinations with platinum-based chemotherapy have demonstrated significant progression-free survival benefit and are becoming the standard of care in first-line settings Cassaniti et al. 2026 Cassaniti et al. 2026. For mismatch repair-proficient (pMMR) tumors, chemo-immunotherapy regimens also provide a more modest yet clinically meaningful benefit Cassaniti et al. 2026 Cassaniti et al. 2026.

Radiotherapy, including external beam radiotherapy (EBRT) and vaginal brachytherapy (VBT), plays an important role as part of multimodal therapy for locoregional control, particularly in residual or bulky pelvic disease and for palliation Cassaniti et al. 2026 NICE CKS. It is commonly used sequentially after systemic therapy and may be integrated concomitantly in select cases with symptomatic pelvic masses Cassaniti et al. 2026 Cassaniti et al. 2026.

HER2 overexpression is more common in uterine serous carcinoma but may be present in clear-cell subtypes, and HER2-targeted therapy with agents like trastuzumab combined with chemotherapy has shown improved outcomes and is recommended where HER2 positivity is confirmed Cassaniti et al. 2026 Cassaniti et al. 2026. Molecular profiling including p53 status, mismatch repair deficiency, and markers like HER2 are vital to inform treatment decisions. Hormone receptor status and other emerging biomarkers may guide additional treatment options such as endocrine therapy in selected patients Cassaniti et al. 2026 Cassaniti et al. 2026.

For platinum-resistant or recurrent disease, immunotherapy with single-agent PD-1 inhibitors (e.g., dostarlimab, pembrolizumab) is preferred in dMMR/MSI-H tumors due to high response rates Cassaniti et al. 2026 Cassaniti et al. 2026. In pMMR patients who progress on platinum therapy, combination therapy with pembrolizumab and lenvatinib (a multikinase inhibitor) is a standard systemic treatment option despite higher toxicity Cassaniti et al. 2026 Cassaniti et al. 2026. Emerging approaches such as PARP inhibitors, antibody–drug conjugates targeting trop-2 or HER2, and novel endocrine strategies are under investigation and may become options in selected molecularly defined subsets Cassaniti et al. 2026 Cassaniti et al. 2026.

Comprehensive management should be undertaken by a multidisciplinary team experienced in gynecologic oncology, integrating surgery, chemotherapy, radiotherapy, and emerging molecularly guided therapies, with personalized consideration of patient performance status and preferences NICE CKS Cassaniti et al. 2026. Enrollment in clinical trials is strongly encouraged due to evolving treatment paradigms.

Summary:

• Consider cytoreductive surgery if complete tumor resection with acceptable morbidity is achievable; otherwise, neoadjuvant chemotherapy followed by interval debulking surgery is an alternative Cassaniti et al. 2026 Cassaniti et al. 2026.
• First-line systemic therapy is carboplatin–paclitaxel chemotherapy combined with immune checkpoint inhibitors, especially in dMMR/MSI-H tumors; chemo-immunotherapy benefits pMMR tumors to a lesser extent Cassaniti et al. 2026 Cassaniti et al. 2026.
• Radiotherapy offers locoregional control and symptom palliation and may be used sequentially or concurrently with systemic therapy NICE CKS Cassaniti et al. 2026.
• Test for HER2 and other molecular markers to guide targeted therapies such as trastuzumab in HER2-positive disease Cassaniti et al. 2026.
• In platinum-resistant or recurrent settings, use single-agent ICIs for dMMR tumors and pembrolizumab plus lenvatinib for pMMR tumors Cassaniti et al. 2026.
• Consider emerging targeted therapies, PARP inhibitors, antibody–drug conjugates, and endocrine therapy based on tumor biology and clinical trial availability Cassaniti et al. 2026.